- Home
- SGML vs GYRE Comparison
SGML vs GYRE Comparison
Compare SGML & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGML
- GYRE
- Stock Information
- Founded
- SGML 2011
- GYRE 2002
- Country
- SGML Brazil
- GYRE United States
- Employees
- SGML N/A
- GYRE N/A
- Industry
- SGML Industrial Machinery/Components
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- SGML Industrials
- GYRE Health Care
- Exchange
- SGML Nasdaq
- GYRE Nasdaq
- Market Cap
- SGML 956.9M
- GYRE 990.4M
- IPO Year
- SGML N/A
- GYRE N/A
- Fundamental
- Price
- SGML $7.14
- GYRE $8.88
- Analyst Decision
- SGML Strong Buy
- GYRE
- Analyst Count
- SGML 2
- GYRE 0
- Target Price
- SGML $18.00
- GYRE N/A
- AVG Volume (30 Days)
- SGML 898.7K
- GYRE 209.4K
- Earning Date
- SGML 05-15-2025
- GYRE 05-19-2025
- Dividend Yield
- SGML N/A
- GYRE N/A
- EPS Growth
- SGML N/A
- GYRE N/A
- EPS
- SGML N/A
- GYRE 0.05
- Revenue
- SGML $145,080,064.00
- GYRE $105,757,000.00
- Revenue This Year
- SGML $76.30
- GYRE $22.01
- Revenue Next Year
- SGML $95.83
- GYRE $88.14
- P/E Ratio
- SGML N/A
- GYRE $184.70
- Revenue Growth
- SGML 15.18
- GYRE N/A
- 52 Week Low
- SGML $6.79
- GYRE $6.11
- 52 Week High
- SGML $19.20
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- SGML 29.87
- GYRE 51.54
- Support Level
- SGML $7.05
- GYRE $7.03
- Resistance Level
- SGML $8.56
- GYRE $8.44
- Average True Range (ATR)
- SGML 0.85
- GYRE 1.12
- MACD
- SGML -0.15
- GYRE 0.23
- Stochastic Oscillator
- SGML 8.11
- GYRE 92.33
About SGML Sigma Lithium Corporation
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds a 100% interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.